Literature DB >> 12669158

Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

R Kubalek1, A Berlis, M Schwab, J Klisch, M Schumacher.   

Abstract

We evaluated the role of the activated clotting time (ACT) and activated partial thromboplastin time (APTT), both currently available as bedside tests, for monitoring anticoagulation following bolus injection of 2500 or 5000 IU heparin in 21 patients undergoing neuroradiological procedures. APTT was measured using the CoaguChek Pro device compared to the laboratory standard measurement and ACT comparing CoaguChek Pro to Hemochron Celite and Kaolin. Statistical analysis was performed using Bablok-Passing regression. Despite heparin doses of 2500-5000 IU APTT measurements were out of range in 67% of patients using CoaguChek Pro and in 76.5% of patients using the laboratory measurement. ACT was reliably determined in all patients. The correlation between the different devices (CoaguChek Pro vs. Hemochron Celite r=0.69, Kaolin r=0.78) and assays (Hemochron Celite/Kaolin r=0.85) was good. ACT ranged from 141-417 s measured by CoaguChek Pro and 138-320 s measured by Hemochron Celite and 172-381 s using Hemochron Kaolin. These results indicate that ACT is the method of choice for monitoring anticoagulation in neuroangiographic procedures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669158     DOI: 10.1007/s00234-003-0975-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  21 in total

1.  [Anticoagulation control during neuroradiological interventions with ACT (activated clotting time)].

Authors:  A Berlis; M Schumacher
Journal:  Rofo       Date:  1999-04

2.  [Complications in cerebral angiography. A study of 6698 cerebral angiographies].

Authors:  R Kachel; U Jahn; R Schiffmann; S Basche
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  1991 Jan-Jun

3.  Relation between activated clotting time during angioplasty and abrupt closure.

Authors:  C R Narins; W B Hillegass; C L Nelson; J E Tcheng; R A Harrington; H R Phillips; R S Stack; R M Califf
Journal:  Circulation       Date:  1996-02-15       Impact factor: 29.690

Review 4.  Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.

Authors:  R J Simko; F F Tsung; E J Stanek
Journal:  Ann Pharmacother       Date:  1995-10       Impact factor: 3.154

5.  Use of the activated coagulation time as a measure of anticoagulation during interventional procedures.

Authors:  J A Scott; A Berenstein; D Blumenthal
Journal:  Radiology       Date:  1986-03       Impact factor: 11.105

6.  Comparison of activated partial thromboplastin time to activated clotting time for adequacy of heparin anticoagulation just before percutaneous transluminal coronary angioplasty.

Authors:  H P Grill; J E Spero; J E Granato
Journal:  Am J Cardiol       Date:  1993-05-15       Impact factor: 2.778

Review 7.  Research review: use of activated clotting time to monitor heparin therapy in coronary patients.

Authors:  S N Noureddine
Journal:  Am J Crit Care       Date:  1995-07       Impact factor: 2.228

8.  Adequate heparinization during PTCA: assessment using activated clotting times.

Authors:  J D Ogilby; H A Kopelman; L W Klein; J B Agarwal
Journal:  Cathet Cardiovasc Diagn       Date:  1989-12

9.  Minimal heparinization in coronary angioplasty--how much heparin is really warranted?

Authors:  E Kaluski; R Krakover; G Cotter; A Hendler; I Zyssman; O Milovanov; A Blatt; E Zimmerman; E Goldstein; V Nahman; Z Vered
Journal:  Am J Cardiol       Date:  2000-04-15       Impact factor: 2.778

10.  Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time.

Authors:  E I Banez; D A Triplett; J Koepke
Journal:  Am J Clin Pathol       Date:  1980-10       Impact factor: 2.493

View more
  1 in total

1.  Anticoagulation management.

Authors:  Blaze W Cook
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.